Page last updated: 2024-08-18

isoquinoline and Hyperemia

isoquinoline has been researched along with Hyperemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, CH; Chen, WR; Chen, YH; Chou, SH; Hsu, CR; Hsu, YL; Huang, JW; Huang, KK; Huang, YC; Hwang, CS; Lee, TC; Lin, CL; Lin, MN; Liu, CP; Lu, DW; Tu, CM	1

Other Studies

1 other study(ies) available for isoquinoline and Hyperemia

Article	Year
A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia. Investigative ophthalmology & visual science, 2019, 02-01, Volume: 60, Issue:2 Topics: Administration, Ophthalmic; Animals; Antihypertensive Agents; Aqueous Humor; Conjunctiva; Disease Models, Animal; Eyelids; Glaucoma; Hyperemia; Incidence; Intraocular Pressure; Isoquinolines; Male; Myosin Light Chains; Ophthalmic Solutions; Phosphorylation; Protein Kinase Inhibitors; Rabbits; rho-Associated Kinases	2019

Article

Year

A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.

Investigative ophthalmology & visual science, 2019, 02-01, Volume: 60, Issue:2

Topics: Administration, Ophthalmic; Animals; Antihypertensive Agents; Aqueous Humor; Conjunctiva; Disease Models, Animal; Eyelids; Glaucoma; Hyperemia; Incidence; Intraocular Pressure; Isoquinolines; Male; Myosin Light Chains; Ophthalmic Solutions; Phosphorylation; Protein Kinase Inhibitors; Rabbits; rho-Associated Kinases

2019